Regeneron Pharmaceuticals’ (REGN) Overweight Rating Reiterated at Cantor Fitzgerald

Cantor Fitzgerald reiterated their overweight rating on shares of Regeneron Pharmaceuticals (NASDAQ:REGN) in a report released on Thursday,Benzinga reports. The firm currently has a $800.00 price target on the biopharmaceutical company’s stock.

A number of other equities research analysts have also recently weighed in on the company. Sanford C. Bernstein reduced their price objective on Regeneron Pharmaceuticals from $925.00 to $921.00 and set an “outperform” rating for the company in a research note on Wednesday, April 8th. Weiss Ratings restated a “hold (c)” rating on shares of Regeneron Pharmaceuticals in a research report on Friday, March 27th. JPMorgan Chase & Co. lifted their target price on shares of Regeneron Pharmaceuticals from $850.00 to $950.00 and gave the company an “overweight” rating in a report on Monday, February 2nd. Piper Sandler assumed coverage on shares of Regeneron Pharmaceuticals in a research report on Tuesday, March 31st. They issued an “overweight” rating and a $875.00 price target for the company. Finally, Zacks Research cut shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Friday, February 6th. Two research analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and eight have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $825.35.

Regeneron Pharmaceuticals Stock Down 1.9%

REGN opened at $751.57 on Thursday. The business’s 50-day simple moving average is $762.84 and its 200-day simple moving average is $732.12. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.39 and a current ratio of 4.13. Regeneron Pharmaceuticals has a one year low of $476.49 and a one year high of $821.11. The stock has a market capitalization of $79.46 billion, a P/E ratio of 18.08, a price-to-earnings-growth ratio of 1.71 and a beta of 0.40.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its earnings results on Friday, January 30th. The biopharmaceutical company reported $11.44 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $10.74 by $0.70. The firm had revenue of $3.88 billion during the quarter, compared to analysts’ expectations of $3.76 billion. Regeneron Pharmaceuticals had a return on equity of 13.04% and a net margin of 31.41%.The business’s revenue was up 2.5% on a year-over-year basis. During the same period in the prior year, the firm earned $12.07 EPS. Analysts anticipate that Regeneron Pharmaceuticals will post 35.2 EPS for the current year.

Regeneron Pharmaceuticals Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Thursday, March 5th. Shareholders of record on Friday, February 20th were paid a $0.94 dividend. This is an increase from Regeneron Pharmaceuticals’s previous quarterly dividend of $0.88. The ex-dividend date was Friday, February 20th. This represents a $3.76 annualized dividend and a dividend yield of 0.5%. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is 9.05%.

Insider Activity

In related news, Director Arthur F. Ryan sold 100 shares of the stock in a transaction on Monday, February 9th. The stock was sold at an average price of $778.53, for a total transaction of $77,853.00. Following the completion of the sale, the director directly owned 17,803 shares of the company’s stock, valued at $13,860,169.59. This trade represents a 0.56% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Huda Y. Zoghbi sold 1,638 shares of Regeneron Pharmaceuticals stock in a transaction on Thursday, February 19th. The shares were sold at an average price of $781.33, for a total transaction of $1,279,818.54. Following the completion of the transaction, the director owned 1,703 shares in the company, valued at approximately $1,330,604.99. This trade represents a 49.03% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders have sold 3,774 shares of company stock valued at $2,942,738. Company insiders own 7.02% of the company’s stock.

Institutional Trading of Regeneron Pharmaceuticals

Several hedge funds have recently made changes to their positions in the company. Insigneo Advisory Services LLC increased its stake in shares of Regeneron Pharmaceuticals by 3.0% during the fourth quarter. Insigneo Advisory Services LLC now owns 445 shares of the biopharmaceutical company’s stock worth $343,000 after acquiring an additional 13 shares during the period. Guardian Wealth Advisors LLC NC lifted its position in Regeneron Pharmaceuticals by 3.3% in the fourth quarter. Guardian Wealth Advisors LLC NC now owns 443 shares of the biopharmaceutical company’s stock valued at $342,000 after purchasing an additional 14 shares during the period. TD Private Client Wealth LLC boosted its holdings in Regeneron Pharmaceuticals by 9.7% in the 4th quarter. TD Private Client Wealth LLC now owns 169 shares of the biopharmaceutical company’s stock valued at $130,000 after purchasing an additional 15 shares in the last quarter. MCF Advisors LLC increased its position in Regeneron Pharmaceuticals by 50.0% during the 4th quarter. MCF Advisors LLC now owns 45 shares of the biopharmaceutical company’s stock worth $35,000 after purchasing an additional 15 shares during the period. Finally, Rexford Capital Inc. increased its position in Regeneron Pharmaceuticals by 5.5% during the 4th quarter. Rexford Capital Inc. now owns 288 shares of the biopharmaceutical company’s stock worth $222,000 after purchasing an additional 15 shares during the period. Institutional investors and hedge funds own 83.31% of the company’s stock.

Key Stories Impacting Regeneron Pharmaceuticals

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: FDA approves Otarmeni (lunsotogene parvec-cwha), the first gene therapy to restore hearing — pivotal CHORD data showed ~80% met the primary endpoint and 42% achieved normal hearing on longer follow‑up, marking a breakthrough product and validating Regeneron’s genetic‑medicine efforts. Read More.
• Positive Sentiment: Analyst support: TD Cowen raised its price target to $960 (buy) and Cantor Fitzgerald reaffirmed an overweight rating with an $800 target — institutional upgrades can support upside as investors re‑rate growth prospects. Read More.
• Positive Sentiment: Regeneron reportedly secured tariff relief from the U.S. government for three years as part of the deal, which mitigates some cost headwinds and is a near‑term financial benefit. Read More.
• Neutral Sentiment: Regeneron will provide Otarmeni for free to eligible U.S. patients — a major access/PR move that increases uptake and public goodwill but has ambiguous near‑term revenue implications. Read More.
• Neutral Sentiment: Q1 preview / estimates: Research outlets (Zacks) are parsing Wall Street’s revenue and key‑metric estimates ahead of quarterly reporting — results will be important for near‑term stock direction. Read More.
• Neutral Sentiment: CEO Leonard Schleifer said Regeneron will provide Otarmeni for free in the U.S. but hasn’t decided on overseas pricing — international price strategy remains uncertain and will affect global revenue potential. Read More.
• Negative Sentiment: Drug‑pricing deal: Regeneron agreed to offer some prescriptions at “most‑favored‑nation” (MFN) prices and to lower U.S. drug costs under the administration deal — investors worry this could compress margins and reduce pricing power across the portfolio. Read More.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.